EU-NCL - 1st call for characterisation of injectable nanomedicines addressing cancer

Up one level
— filed under: , ,

The recently established European Nanomedicine Characterisation Laboratory (EU-NCL) aims at providing critical infrastructure and characterisation services that are needed to analyse physical and chemical attributes, in vitro biological properties, and in vivo characteristics of emerging nanomedicines ready for translation and clinical trials.

The first characterisation campaign will be dedicated to medicinal nanoparticles based on organic compounds with proposed application in cancer treatment and/or diagnosis via the intravenous route.

The submission deadline for the first campaign is 15th April 2016.


More information on the application procedure can be found at

Document Actions